Centrient Pharmaceuticals* joins the EU’s Joint Industrial Cooperation Forum to support Europe’s health security and pharmaceutical resilience
- Centrient joins the Joint Industrial Cooperation Forum to support Europe’s healthcare resilience and contributes to efforts aimed at ensuring continued access to essential medicines
- This initiative builds on our role in the Critical Medicines Alliance and leverages Centrient’s European manufacturing capabilities – including sites in Spain and the Netherlands - and backward-integrated biomanufacturing network to help address supply chain vulnerabilities and support EU preparedness
Centrient Pharmaceuticals has announced that it has joined the European Union’s Joint Industrial Cooperation Forum (JICF), a key platform that brings together Member States and industry to reinforce the security of Europe’s healthcare supply chains. Co-chaired by the EU’s Health Emergency Preparedness and Response Authority (HERA) and DG GROW, the Forum focuses on practical, coordinated solutions to ensure that essential medicines remain available during times of crisis and beyond.
This step builds on Centrient’s membership to the EU’s Critical Medicines Alliance (CMA) and reflects our view that Europe's health security depends on the need for a stable supply chain, strong local manufacturing, and close collaboration between industry and policymakers.
As one of the last remaining companies with European manufacturing capabilities for critical antibiotics, Centrient recognizes the importance of reliable access to medicines, not only for patients but for the stability of healthcare systems. Centrient operates a backward-integrated biomanufacturing network across multiple regions, with strong capabilities in Europe that help dampen supply shocks and protect healthcare access. By joining the JICF, Centrient will contribute operational expertise and data-driven insights to help address bottlenecks, strengthen supply chains, and support Europe’s preparedness for future health challenges.
Rex Clements, Chief Executive Officer at Centrient, comments: “Patients deserve certainty. That's why we believe Europe should develop a strong manufacturing footprint and support the local industry. Our role in the JICF is about turning that into practical steps that shore up supply chains, avoid shortages, and keep essential medicines available.”
The JICF provides a structured environment for dialogue and action, enabling industry and policymakers to work together on risk mapping, capacity planning and industrial matchmaking. For Centrient, it’s a chance to share expertise, anticipate challenges and co-create solutions that strengthen healthcare systems across Europe. We view resilience not as a policy aspiration but as a shared obligation to keep essential medicines available at all times.
----------------------------------------------------------------------------------------------------------------
About Centrient Pharmaceuticals
Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals. We are a pharmaceutical company with a clear Purpose: to improve lives through innovative and sustainable manufacturing of medicines - saving the lives of millions of people around the world annually. Regarding our portfolio, we produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as finished dosage forms (FDFs). Centrient Pharmaceuticals is a Board Member of the AMR Industry Alliance and a long-time advocate for industry responsibility in manufacturing. For more information, please visit www.centrient.com, www.linkedin.com/company/centrient or contact Centrient Pharmaceuticals Global Communications and ESG Director, Neil Moorhouse. E-Mail: neil.moorhouse@centrient.com.
*( 1) “Centrient Pharmaceuticals”, “Centrient” in this content are sometimes used for convenience where references are made to Centrient International Pharmaceuticals B.V, and or one or more of its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Centrient Pharmaceuticals International B.V. and or one or more of its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. “Subsidiaries”, “Centrient subsidiaries” and “Centrient companies” as used in this content refer to entities over which Centrient Pharmaceuticals International B.V. either directly or indirectly has control. The term “Centrient interest” is used for convenience to indicate the direct and/or indirect ownership interest held by Centrient Pharmaceuticals International B.V. in an entity or unincorporated joint arrangement, after exclusion of all third-party interest.